Abstract:Background/Aims: Neurotrophic effects and immunosuppression are the main therapeutic mechanisms of mesenchymal stem cells (MSCs) in stroke treatment. Neurotrophins are produced by graft cells, host neurons, astrocytes, and even microglia/macrophages. Meanwhile, MSCs can increase inflammation if they are not sufficiently induced by pro-inflammatory cytokines. We examined whether intravenously transplanted bone marrow MSCs (BM-MSCs) increase inflammation in distal middle cerebral artery occlusion (dMCAO) rats, how long the increased inflammation effect persists for, and what the final therapeutic outcomes will be. We also tested the neurotrophic role of BM-MSCs and attempted to identify the neurotrophin-producing cells. Methods: At 1 h after dMCAO was performed on Sprague-Dawley rats, allogeneic BM-MSCs were transplanted intravenously. The infarct volume was examined by Tetrazolium Red staining at 2 days (day 2), and the behavioral tests (cylinder test and grid walking test) were performed at 2, 4 (day 4) and 7 days (day 7) after transplantation. The concentrations of inflammation related cytokines and neurotrophins in the ischemic cortex, ipsilateral striatum, and serum, were measured using ELISA at days 2-7. The cell source of neurotrophins was observed by immunohistochemistry. Results: The transplanted cells were mainly found in the infarct border zone (IBZ) of the brain. Infarct volume was reduced and behavioral outcomes were improved at 2 days after ischemia. In the striatum and circulation. BM-MSC transplantation increased inflammation at day 2 and decreased it at day 7. At days 2-7, insulin-like growth factor-1 (IGF-1) and brain-derived neurotrophic factor (BDNF) concentrations in the ischemic core of the cortex were significantly higher in the BM-MSC group than in the ischemia vehicle group. IGF-1 and BDNF were derived mainly from host microglia/macrophages in the ischemic core, and transplanted cells in the IBZ. At day 2, BM-MSC transplantation significantly increased the number of IGF-1(+)CD68(+) and BDNF(+)Iba-1(+) double positive cells in the ischemic core cortex. Conclusions: Although increased inflammation, BM-MSCs were still beneficial to dMCAO recovery at day 2. The immunopromoting effect of MSCs was transient and shifted to an immunosuppressive action at day 7. The neurotrophic factors IGF-1 and BDNF, which were mainly derived from transplanted BM-MSCs and host microglia/macrophages, contributed to the therapeutic effects from day 2 to day 7. (C) 2018 The Author(s) Published by S. Karger AG, Basel

Bone marrow-derived mesenchymal stem cell ameliorates post-stroke enterobacterial translocation through liver-gut axis

Gut Microbiota-Mediated Ursodeoxycholic Acids Regulate the Inflammation of Microglia Through TGR5 Signaling after MCAO.

Abstract TMP29: Mesenchymal Stromal Cell Administration Attenuates Post-Stroke Susceptibility to Spontaneous Infection Through Prevention of Caspase-1-Dependent Splenic Marginal Zone B Cell Death

Characteristics of Intestinal Microecology During Mesenchymal Stem Cell-Based Therapy for Mouse Acute Liver Injury

Bone Marrow Mesenchymal Stem Cell‐Derived Dermcidin‐Containing Migrasomes enhance LC3‐Associated Phagocytosis of Pulmonary Macrophages and Protect against Post‐Stroke Pneumonia

Immunosuppressive Effect Of Mesenchymal Stem Cells On Lung And Gut Cd8(+) T Cells In Lipopolysaccharide-Induced Acute Lung Injury In Mice

Intravenous Transplantation of Mesenchymal Stem Cells Reduces the Number of Infiltrated Ly6C+ Cells but Enhances the Proportions Positive for BDNF, TNF-1α, and IL-1β in the Infarct Cortices of Dmcao Rats

Targeted homing of CCR2-overexpressing mesenchymal stromal cells to ischemic brain enhances post-stroke recovery partially through PRDX4-mediated blood-brain barrier preservation.

Exosomes derived from microRNA-138-5p-overexpressing bone marrow-derived mesenchymal stem cells confer neuroprotection to astrocytes following ischemic stroke via inhibition of LCN2

Exosomes from bone marrow mesenchymal stem cells are a potential treatment for ischemic stroke

Mesenchymal stem cells attenuate blood-brain barrier leakage after cerebral ischemia in mice

Correction To: Exosomes Derived from Microrna-138-5poverexpressing Bone Marrow-Derived Mesenchymal Stem Cells Confer Neuroprotection to Astrocytes Following Ischemic Stroke Via Inhibition of LCN2

Bone marrow mesenchymal stem cells therapy regulates sphingolipid and glycerophospholipid metabolism to promote neurological recovery in stroke rats: A metabolomics analysis

Mesenchymal stem cell therapy for ischemic stroke: Novel insight into the crosstalk with immune cells

A comparative study of different doses of bone marrow-derived mesenchymal stem cells improve post-stroke neurological outcomes via intravenous transplantation

Mitochondrial Transplantation and Immune Response of Human Bone Marrow Mesenchymal Stem Cells for the Therapeutic of Ischemic Stroke.

Bone Marrow-Derived Mesenchymal Stem Cells Overexpressed with Mir-182-5p Protects Against Brain Injury in a Mouse Model of Cerebral Ischemia.

Neuroprotective effects of exosomes derived from bone marrow mesenchymal stem cells treated by Musk Ketone on ischemic stroke rats

Intravenously Delivered Allogeneic Mesenchymal Stem Cells Bidirectionally Regulate Inflammation and Induce Neurotrophic Effects in Distal Middle Cerebral Artery Occlusion Rats Within the First 7 Days After Stroke.

Effects and Mechanisms of Bone Marrow Mesenchymal Stem Cell Transplantation for Treatment of Ischemic Stroke in Hypertensive Rats.

BM-MSC Transplantation Alleviates Intracerebral Hemorrhage-Induced Brain Injury, Promotes Astrocytes Vimentin Expression, and Enhances Astrocytes Antioxidation Via the Cx43/Nrf2/HO-1 Axis.